Patents Examined by Marcela M. Cordero Garcia
  • Selectin inhibitors, composition, and uses related thereto
    Patent number: 10253071
    Abstract: This disclosure relates to selectin inhibitors, compositions, and methods related thereto. In certain embodiments, the disclosure relates to glycopeptides that contain one more modified amino acids conjugated to a saccharide or polysaccharide. In certain embodiments, the disclosure relates to uses of the glycopeptides as anti-inflammatory, anti-thrombotic, or anti-metastatic agents.
    Type: Grant
    Filed: May 23, 2014
    Date of Patent: April 9, 2019
    Assignees: Beth Israel Deaconess Medical Center, Inc., Emory University
    Inventors: Richard D. Cummings, Elliot L. Chaikof, Venkata R. Krishnamurthy, Mohammed Sardar
  • Peptidomimetic macrocycles and uses thereof
    Patent number: 10253067
    Abstract: Methods for treating liquid cancer, determined to lack a p53 deactivation mutation, in a subject are provided. Also provided are peptidomimetic macrocycles for use in treatment of a liquid cancer, determined to lack a p53 deactivation mutation, in a subject.
    Type: Grant
    Filed: March 18, 2016
    Date of Patent: April 9, 2019
    Assignee: Aileron Therapeutics, Inc.
    Inventors: Hubert Chen, David Allen Annis, Yong Chang, Manuel Aivado, Karen Olson, Chris Viau
  • Purification method, purification kit, and silicon oxide-binding tag for use therein
    Patent number: 10253064
    Abstract: The present invention provides a method for purifying an intended substance, a kit for purifying the intended substance, and a silicon oxide-binding tag for use in the method and the kit. In the present invention, a complex of a silicon oxide-binding tag and a substance is caused to specifically bind to silicon oxide in a solution for binding, to which solution no salt is added, and binding between the silicon oxide-binding tag and the silicon oxide is broken with use of arginine.
    Type: Grant
    Filed: October 21, 2015
    Date of Patent: April 9, 2019
    Assignee: Hiroshima University
    Inventors: Akio Kuroda, Takeshi Ikeda, Hisakage Funabashi
  • Hydrolyzed collagen compositions and methods of making thereof
    Patent number: 10253090
    Abstract: Disclosed herein are hydrolyzed collagen compositions. The compositions are inexpensive to make and can be produced without the use of proteolytic enzymes, decolorizing agents, antibacterial and antifungal agents, and the like. Further, the compositions are substantially free of odors and are white to light yellow in color and are suitable to be used as dietary supplements. Also disclosed are methods for producing the compositions.
    Type: Grant
    Filed: March 20, 2017
    Date of Patent: April 9, 2019
    Assignee: Avicenna Nutraceutical, LLC
    Inventors: Ali Elnajjar, Ali Mourad, Mark Ernst Brandt, Christopher Lippelt
  • Selective PYY compounds and uses thereof
    Patent number: 10246497
    Abstract: The invention relates to PYY compounds having the amino acid in the position corresponding to position 30 of hPYY(1-36) substituted with tryptophan and derivatives thereof with a modifying group attached to the position corresponding to position 7 of hPYY(1-36). The compounds of the invention are selective Y2 receptor agonists. The invention also relates to pharmaceutical compositions comprising such PYY compounds and pharmaceutically acceptable excipients, as well as the medical use of the PYY compounds.
    Type: Grant
    Filed: November 13, 2014
    Date of Patent: April 2, 2019
    Assignee: Novo Nordisk A/S
    Inventors: Soeren Oestergaard, Kilian Waldemar Conde Frieboes, Birgit Wieczorek, Jens Kaalby Thomsen, Birgitte Schjellerup Wulff, Carsten Jessen
  • Use of inhibitory peptides for the treatment of inflammatory diseases
    Patent number: 10246488
    Abstract: An isolated peptide is disclosed which comprises an amino acid sequence being at least 80% homologous to the sequence as set forth in SEQ ID NO: 1 (PERYQNLSPV), the isolated peptide comprising a nuclear targeting activity, the peptide being no longer than 20 amino acids.
    Type: Grant
    Filed: June 15, 2017
    Date of Patent: April 2, 2019
    Assignee: Yeda Research and Development Co. Ltd.
    Inventors: Rony Seger, Eldar Zehorai
  • Selective delivery molecules and methods of use
    Patent number: 10239919
    Abstract: Disclosed herein is a selective delivery molecule comprising: (a) an acidic sequence (portion A) which is effective to inhibit or prevent the uptake into cells or tissue retention, (b) a molecular transport or retention sequence (portion B), and (c) a linker between portion A and portion B, and (d) at least one cargo moiety.
    Type: Grant
    Filed: November 7, 2017
    Date of Patent: March 26, 2019
    Assignee: AVELAS BIOSCIENCES, INC.
    Inventors: Jesus Gonzalez, Junjie Liu
  • Methods and compositions for detection of cancer
    Patent number: 10238757
    Abstract: A molecular probe for use in detection of cancer cells expressing an Ig superfamily cell adhesion molecule that binds in a homophilic fashion in a subject includes a targeting agent that specifically binds to and/or complexes with a proteolytically cleaved extracellular fragment of the Ig superfamily cell adhesion molecule.
    Type: Grant
    Filed: February 24, 2014
    Date of Patent: March 26, 2019
    Assignee: CASE WESTERN RESERVE UNIVERSITY
    Inventor: Susann Brady-Kalnay
  • Method for identifying novel minor histocompatibility antigens
    Patent number: 10239917
    Abstract: A novel method for human minor histocompatibility antigen (MiHA) discovery, novel MiHAs identified using this method, as well as uses of the novel MiHAs, are described. One of the features of the novel method is the inclusion of personalized translated transcriptome and/or exome in the database used for peptide identification by mass spectroscopy (MS). Candidate MiHAs are identified by comparing the personalized transcriptome and/or exome to a reference genome and/or to the transcriptome and/or exome of an HLA-matched subject.
    Type: Grant
    Filed: October 20, 2016
    Date of Patent: March 26, 2019
    Assignee: UNIVERSITÉ DE MONTRÉAL
    Inventors: Claude Perreault, Pierre Thibault, Sébastien Lemieux, Diana Paola Granados, Sriranganadane Dev, Mohamed Tariq Daouda, Olivier Caron-Lizotte
  • Formulations of guanylate cyclase C agonists and methods of use
    Patent number: 10232011
    Abstract: The invention provides low-dose formulations of guanylate cyclase-C (“GCC”) agonist peptides and methods for their use. The formulations of the invention can be administered either alone or in combination with one or more additional therapeutic agents, preferably an inhibitor of cGMP-dependent phosphodiesterase or a laxative.
    Type: Grant
    Filed: March 19, 2018
    Date of Patent: March 19, 2019
    Assignee: SYNERGY PHARMACEUTICALS, INC.
    Inventors: Stephen Comiskey, Rong Feng, John Foss, Kunwar Shailubhai
  • Carrier-free biologically-active protein nanostructures
    Patent number: 10226510
    Abstract: The present disclosure provides compositions and methods for efficient and effective protein delivery in vitro and in vivo. In some aspects, proteins are reversibly crosslinked to each other and/or modified with functional groups and protected from protease degradation by a polymer-based or silica-based nanoshell.
    Type: Grant
    Filed: March 27, 2017
    Date of Patent: March 12, 2019
    Assignee: MASSACHUSETTS INSTITUTE OF TECHNOLOGY
    Inventors: Li Tang, Darrell J. Irvine
  • Compositions and methods for treating diabetes
    Patent number: 10220069
    Abstract: The present invention relates to the field of diabetes mellitus. More specifically, the present invention provides compositions and methods useful for treating diabetes. In another embodiment, a method for treating type 2 diabetes mellitus or pre-diabetes in a patient comprises administering to the patient an effective amount of inhibitor of kisspeptin 1 and/or proteolytic derivatives thereof.
    Type: Grant
    Filed: January 22, 2015
    Date of Patent: March 5, 2019
    Assignee: The Johns Hopkins University
    Inventors: Mehboob Hussain, Prosenjit Mondal, Woo-Jin Song
  • Formulations of diluted amino acid segments and methods for making same
    Patent number: 10213486
    Abstract: A formulation of a diluted amino acid fragment is prepared by mixing an amino acid fragment and a diluting agent to form a mixture. The mixture is serially diluted to produce a diluted formulation. The amino acid fragment includes a peptide sequence that is the same as a portion of a longer peptide sequence found in a naturally occurring material. A homeopathic remedy can be prepared using the formulation.
    Type: Grant
    Filed: March 27, 2017
    Date of Patent: February 26, 2019
    Assignee: Deseret Biologicals, Inc.
    Inventors: Jacob L. Carter, Edwin Douglas Lephart
  • Site-specific antibody-drug conjugation through glycoengineering
    Patent number: 10214589
    Abstract: The current disclosure provides binding polypeptides (e.g., antibodies), and effector moiety conjugates thereof (e.g., antibody-drug conjugates or ADCs), comprising a site-specifically engineered drug-glycan linkage within native or engineered glycans of the binding polypeptide. The current disclosure also provides nucleic acids encoding the antigen-binding polypeptides, recombinant expression vectors and host cells for making such antigen-binding polypeptides. Methods of using the antigen-binding polypeptides disclosed herein to treat disease are also provided.
    Type: Grant
    Filed: January 27, 2017
    Date of Patent: February 26, 2019
    Assignee: GENZYME CORPORATION
    Inventors: Clark Pan, Qun Zhou, James Stefano, Pradeep Dhal, Bo Chen, Diego Gianolio, Robert Miller, Huawei Qiu
  • Method for assessing protein identity and stability
    Patent number: 10209261
    Abstract: The present invention relates to methods and other technologies that may be used to determine whether compositions (e.g., pharmaceutical compositions) comprising interleukin-10 molecules (e.g., pegylated interleukin-10) meet particular product-related specifications prior to being administered to a subject for the treatment and/or prevention of the diseases, disorders and conditions, and/or the symptoms thereof, described herein.
    Type: Grant
    Filed: October 13, 2017
    Date of Patent: February 19, 2019
    Assignee: Armo Biosciences Inc.
    Inventors: John Brian Mumm, Peter Van Vlasselaer
  • SRM/MRM assay for the tyrosine-protein kinase receptor UFO (AXL) protein
    Patent number: 10203336
    Abstract: Peptides from the tyrosine-protein kinase receptor UFO protein (AXL) are provided that are particularly advantageous for quantifying the AXL protein directly in biological samples that have been fixed in formalin by the method of Selected Reaction Monitoring (SRM)/Multiple Reaction Monitoring (MRM) mass spectrometry. Such biological samples are chemically preserved and fixed and include formalin-fixed tissue/cells, formalin-fixed/paraffin embedded (FFPE) tissue/cells, FFPE tissue blocks and cells from those blocks. A protein digest is prepared from the biological sample and the AXL protein is quantitated in the Liquid Tissue sample by the method of SRM/MRM mass spectrometry by quantitating in the protein sample at least one or more of the peptides described.
    Type: Grant
    Filed: April 30, 2015
    Date of Patent: February 12, 2019
    Assignee: Expression Pathology, Inc.
    Inventors: David B. Krizman, Todd Hembrough, Adele Blackler, Wei-Li Liao
  • Kisspeptin-54 detection by tandem mass spectrometry
    Patent number: 10203337
    Abstract: Methods are described for measuring the amount of a kisspeptin-54-derived peptides in a sample. More specifically, mass spectrometric methods are described for detecting and quantifying a kisspeptin-54 derived peptides in a sample utilizing on-line extraction methods coupled with tandem mass spectrometric techniques.
    Type: Grant
    Filed: January 19, 2018
    Date of Patent: February 12, 2019
    Assignee: Quest Diagnostics Investments Incorporated
    Inventors: Cory E. Bystrom, Richard E. Reitz
  • Tumor-targeting compounds
    Patent number: 10202421
    Abstract: The invention relates to a novel compounds targeting human cancer cells, a method for synthesis of such compounds, and use of such compounds in treating cancer.
    Type: Grant
    Filed: September 2, 2016
    Date of Patent: February 12, 2019
    Inventor: Andre Koltermann
  • Red-shifted luciferase-luciferin pairs for enhanced bioluminescence
    Patent number: 10202584
    Abstract: A bioluminescent protein is provided that includes a substituted luciferase polypeptide having amino acid substitutions at positions 21 and 166, and with one or more additional amino acid substitutions at positions 3, 16, 20, 29, 30, 71, 87, 114, and 144, compared to the parent polypeptide. Also provided is a luciferin that has a selenium-containing group at position C8 of an imidazopyrazine backbone, and methods of making the luciferin. In addition, nucleic acids encoding the bioluminescent protein, cells expressing the bioluminescent protein, and reactions between the bioluminescent protein and luciferin substrates are also provided. Fusions between the substituted luciferase polypeptide and a fluorescent protein are also provided for bioluminescence resonance energy transfer based reporters.
    Type: Grant
    Filed: September 1, 2017
    Date of Patent: February 12, 2019
    Assignee: The Regents of the University of California
    Inventors: Huiwang Ai, Hsien-Wei Yeh
  • Selective delivery molecules and methods of use
    Patent number: 10202422
    Abstract: Disclosed herein is a selective delivery molecule comprising: (a) an acidic sequence (portion A) which is effective to inhibit or prevent the uptake into cells or tissue retention, (b) a molecular transport or retention sequence (portion B), and (c) a linker between portion A and portion B, and (d) at least one cargo moiety.
    Type: Grant
    Filed: November 7, 2017
    Date of Patent: February 12, 2019
    Assignee: AVELAS BIOSCIENCES, INC.
    Inventors: Jesus Gonzalez, Junjie Liu